https://allsci.com/news/approvals/icotrokinra-plaque-psoriasis-european-commission/ AllScien 2026-09-21T16:41:14.064215Z J&J's Icotyde adds EU approval for plaque psoriasis. https://allsci.com/news/venture-financing/lrrk2-parkinsons-disease-anacalypsis-raises/ AllScien 2026-09-21T16:34:21.336137Z Greek startup Anacalypsis gets seed funding for non-kinase LRRK2 strategy in Parkinson’s https://allsci.com/news/approvals/obicetrapib-approval-europe-european-commission/ AllScien 2026-09-21T16:30:12.953464Z Menarini, NewAmsterdam win EU approval for first CETP inhibitor in hypercholesterolemia https://allsci.com/news/debt-financing/halozyme-convertible-offering-prices-upsized-usd/ AllScien 2026-09-21T16:22:50.810564Z Halozyme prices upsized USD 1.3b convertible offering to extend ENHANZE's IP runway https://allsci.com/news/xenetic-santersus-acquisition-agrees-to-acquire/ AllScien 2026-09-21T16:15:47.787294Z Xenetic to acquire Santersus in NET-targeting biotech combination https://allsci.com/news/approvals/inluriyo-verzenio-breast-cancer-fda-approval/ AllScien 2026-09-21T15:49:50.767554Z Lilly wins FDA approval for Inluriyo-Verzenio breast cancer combo https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-platform-hanx/ AllScien 2026-09-21T15:44:25.240550Z Hanx Bio licenses XtalPi AI drug discovery platform for biologics R&D https://allsci.com/news/clinical-trials/adhd-orexin-agonist-alkermes-shows-dose-dependent/ AllScien 2026-09-21T15:39:58.709830Z Alkermes’ orexin agonist shows dose-dependent ADHD symptom reductions in Phase Ib study https://allsci.com/news/clinical-trials/caplyta-bipolar-mania-trial-beats-placebo-in/ AllScien 2026-09-21T15:30:47.245762Z J&J’s Caplyta posts rapid Phase III benefit in bipolar mania https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-collaboration-abbvie-partners/ AllScien 2026-09-21T15:01:53.525909Z AbbVie partners with Iambic to apply AI platform across immunology, neuroscience, and oncology https://allsci.com/news/development/fda-priority-review-arikayce-grants-to-insmeds/ AllScien 2026-09-21T14:58:16.177559Z Insmed’s Arikayce label expansion filing gets January 2027 PDUFA date https://allsci.com/news/clinical-trials/vnx-101-gene-therapy-all-achieves-mrd-negative/ AllScien 2026-09-21T14:53:08.181205Z Vironexis reports early durable ALL responses with one-time AAV therapy https://allsci.com/news/regulatory-designations-pathways/dersimelagon-fda-priority-review-leo-pharma-gains/ AllScien 2026-09-21T14:40:55.055888Z LEO Pharma gains priority review for Tanabe-acquired oral therapy for rare porphyrias https://allsci.com/news/regulatory-setbacks-safety/anaphylm-nda-fda-resubmission-aquestive-resubmits/ AllScien 2026-09-21T14:26:17.718606Z Anaphylm returns to FDA after Aquestive addresses usability, PK concerns https://allsci.com/news/clinical-trials/xlrp-gene-therapy-beacons-laru-zova-becomes-first/ AllScien 2026-09-21T14:19:25.255448Z Beacon's laru-zova becomes first XLRP gene therapy to meet pivotal trial primary endpoint https://allsci.com/news/development/azetukalner-fda-approval-focal-seizures/ AllScien 2026-09-21T13:09:00.718453Z Xenon files azetukalner NDA for focal seizures as KV7 revival, pauses psychiatry trials https://allsci.com/news/clinical-trials/cue-221-phase-ii-csu-cues-meets-primary-endpoint/ AllScien 2026-09-21T12:38:24.494585Z Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria https://allsci.com/news/china-pharmaceutical-five-year-plan-chinas-ten/ AllScien 2026-09-21T12:06:26.376836Z China targets 25% of global first-in-class drugs by 2030 in new pharma five-year-plan https://allsci.com/news/clinical-trials/tyk2-inhibitor-psoriasis-hansohs-hs-10374-meets/ AllScien 2026-09-21T11:27:03.087282Z Hansoh's TYK2 inhibitor HS-10374 meets Phase III endpoints in moderate-to-severe psoriasis https://allsci.com/news/clinical-trials/atg-022-phase-iii-trial-gastric-cancer-antengene/ AllScien 2026-09-21T11:06:39.476952Z Antengene launches pivotal Phase III trial of ATG-022 in third-line gastric cancer https://allsci.com/news/clinical-trials/lavengratinib-achondroplasia-trial-abbiskos/ AllScien 2026-09-21T10:29:22.663060Z Abbisko's lavengratinib achieves 100% responder rate in early achondroplasia trial https://allsci.com/news/telix-itm-acquisition-radioisotope-acquires/ AllScien 2026-09-21T10:18:56.167117Z Telix acquires ITM Isotope Technologies for USD 1.65b to secure radioisotope supply chain https://allsci.com/news/regulatory-policy/pharma-licensing-deals-china-us-treasury-drafts/ AllScien 2026-09-21T10:06:32.472403Z US Treasury reportedly drafting rules to preserve pharma licensing deals with China https://allsci.com/news/licensing-and-partnerships/novo-nordisk-obesity-acquisition-acquires-three/ AllScien 2026-09-21T08:53:37.077928Z Novo acquires three early-stage obesity programs from Columbia-linked Kallyope